ProMIS Neurosciences Inc. (PMN)
NASDAQ: PMN
· Real-Time Price · USD
0.51
-0.00 (-0.58%)
At close: Jun 17, 2025, 2:10 PM
-0.58% (1D)
| Bid | 0.51 |
| Market Cap | 16.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -933.94K |
| EPS (ttm) | 0.09 |
| PE Ratio (ttm) | 5.61 |
| Forward PE | -0.66 |
| Analyst | Buy |
| Ask | 0.51 |
| Volume | 14,388 |
| Avg. Volume (20D) | 48,758.2 |
| Open | 0.51 |
| Previous Close | 0.51 |
| Day's Range | 0.50 - 0.53 |
| 52-Week Range | 0.47 - 2.37 |
| Beta | -0.08 |
Analyst Forecast
According to 0 analyst ratings, the average rating for PMN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+5.83%
ProMIS Neurosciences shares are trading higher aft...
Unlock content with
Pro Subscription
10 months ago
-17.47%
ProMIS Neurosciences shares are trading lower. The company presented preclinical data at the 2024 Alzheimer's Association International Conference.
2 years ago · proactiveinvestors.com
ProMIS Neurosciences submits IND application for Alzheimer's treatmentProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's di...